Showing 4941-4950 of 7518 results for "".
- Provectus Biopharmaceuticals Appoints Christopher Kaplan to Its Strategic Advisory Boardhttps://practicaldermatology.com/news/20140922-provectus_biopharmaceuticals_appoints_christopher_kaplan_to_its_strategic_advisory_board/2459110/Christopher Kaplan, currently President of Cajetan, LLC, will now be appointed to Provectus Biopharmaceuticals Strategic Advisory Board. Mr. Kaplan started his pharmaceutical career at Bristol-Myers Squibb Company. He moved quickly through various roles in US sales and sales management and
- Clinical Trials Designed to Block Autophagy in Multiple Cancers, Including Melanoma, Show Promisehttps://practicaldermatology.com/news/20140606-clinical_trials_designed_to_block_autophagy_in_multiple_cancers_including_melanoma_show_promise/2459217/
- AAD Issues Statement on Drinkable Sunscreenhttps://practicaldermatology.com/news/20140523-aad_issues_statement_on_drinkable_sunscreen/2459231/
- Free Drug Samples May Influence Prescribing Habitshttps://practicaldermatology.com/news/20140417-free_drug_samples_may_influence_prescribing_habits/2459266/Results of a study published online on April 16 in JAMA Dermatology found that the availability of free medication samples in dermatology offices appears to change pr
- Merz North America Introduces Mederma PMhttps://practicaldermatology.com/news/20140331-merz_north_america_introduces_mederma_pm/2459290/
- Anti-Interleukin-23 Monoclonal Antibody Guselkumab: Significant Efficacy In Moderate To Severe Plaque Psoriasishttps://practicaldermatology.com/news/20140324-anti-interleukin-23_monoclonal_antibody_guselkumab_significant_efficacy_in_moderate_to_severe_plaque_psoriasis/2459298/New findings presented for the first time at the 2014 Annual Meeting of the American Academy of Dermatology (AAD) showed up to 86 percent of patients with moderate to severe plaque psoriasis receiving guselkumab (CNTO 1959) achieved a Physician's Global Assessment (PGA) score of cleared or minimal a
- Pollogen to Launch FDA-Cleared Imogen at AAD Annual Meetinghttps://practicaldermatology.com/news/20140318-pollogen_to_launch_fda-cleared_imogen_at_aad_annual_meeting/2459312/
- Dr. Zein Obagi to Introduce New ZO Skin Health Treatment Systems At The 2014 AAD Annual Meetinghttps://practicaldermatology.com/news/20140306-dr_zein_obagi_to_introduce_new_zo_skin_health_treatment_systems_at_the_2014_aad_annual_meeting/2459323/
- Ipsen Announces Clinical Results of Dysport Next Generationhttps://practicaldermatology.com/news/20140205-ipsen_announces_clinical_results_of_dysport_next_generation/2459348/
- Oculus Innovative Sciences Receives European CE Mark for Use of Microcyn to Treat Mild to Moderate Acnehttps://practicaldermatology.com/news/20140204-oculus_innovative_sciences_receives_european_ce_mark_for_use_of_microcyn_to_treat_mild_to_moderate_acne/2459350/